NDA 017533 · Cheplapharm
Klonopin
Clonazepam · Oral · Benzodiazepine
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1975
Jun 4, 1975
Approved uses
2
Original approval plus efficacy supplements
Registered trials
53
9 Phase 3, 1 recruiting
FAERS reports
161,077
109,687 serious, 18,794 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including Klonopin, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing Klonopin and...
What it is approved for
From the label in effect Dec 1, 2025.
INDICATIONS AND USAGE Seizure Disorders Klonopin is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, Klonopin may be useful. Some loss of effect may occur during the course of clonazepam treatment (see PRECAUTIONS: Loss of Effect ). Panic Disorder Klonopin is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Klonopin was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-V) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of Klonopin in long-term...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 9, 1997 Supplement 23 · Efficacy
- Jun 4, 1975 Original approval · Type 1 - New Molecular Entity · priority review
5 products under this application
- KLONOPIN · CLONAZEPAM 0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- KLONOPIN · CLONAZEPAM 1MG · TABLET, ORAL · Prescription · TE AB
- KLONOPIN · CLONAZEPAM 0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- KLONOPIN · CLONAZEPAM 2MG · TABLET, ORAL · Prescription · TE AB
- KLONOPIN · CLONAZEPAM 0.5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Clonazepam" as an intervention, any sponsor and status, largest first.
- Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status EpilepticusPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01870024 · 434 participants · Start Jun 26, 2013 · Primary completion Feb 23, 2018
Drug: Clonazepam; Fosphenytoin and 2 more · For: Status Epilepticus; Epilepsy
Sites: Paris, France
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety DisorderPivotal-lookingCompleted
Massachusetts General HospitalAcademic, hospital or other
NCT00282828 · 397 participants · Start Mar 2006 · Primary completion Dec 2011
Drug: Sertraline; Venlafaxine and 2 more · For: Social Phobia
Sites: La Jolla, California; Boston, Massachusetts; Hamilton, Canada
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01713946 · 366 participants · Start Apr 29, 2013 · Primary completion Oct 25, 2017
Drug: RAD001; Placebo and 2 more · For: Tuberous Sclerosis Complex-associated Refractory Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 104 sites in all
- A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive EpisodesPivotal-lookingNot yet recruiting
Jawaharlal Institute of Postgraduate Medical Education & ResearchGovernment (non-federal)
NCT07839338 · 220 participants (planned) · Start Oct 2026 · Primary completion Oct 2029
Drug: Oral ketamine; Oral midazolam · For: Major Depressive Episode
Sites: Bangalore, India; Udupi, India; Mumbai, India · 5 sites in all
- Study of Antiepileptic Drug in Generalised Convulsive Status EpilepticusPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01150331 · 203 participants · Start Jul 2009 · Primary completion May 2013
Drug: Levetiracetam/Clonazepam; Clonazepam/Placebo levetiracetam IV · For: Status; Epilepticus, Tonic-clonic
Sites: Paris, France
- Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00859872 · 198 participants · Start Aug 2008 · Primary completion Mar 2009
Drug: risperidone oral solution; haloperidol · For: Schizophrenia
Sites: Changsha, China
- Ketogenic Diet in Infants With Epilepsy (KIWE)Pivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT02205931 · 160 participants (planned) · Start Jan 2015 · Primary completion Jun 2018
Drug: Antiepileptic drug therapy · For: Epilepsy
Sites: Birmingham, United Kingdom; Bristol, United Kingdom; Cambridge, United Kingdom · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective14,148
- fatigue10,591
- nausea9,904
- anxiety8,957
- headache8,819
- pain8,324
- depression8,277
- off label use8,149
- dizziness7,466
- insomnia7,179
- dyspnoea7,174
- fall6,901
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,222 |
| 2005 | 2,971 |
| 2006 | 2,758 |
| 2007 | 2,680 |
| 2008 | 3,066 |
| 2009 | 3,991 |
| 2010 | 5,734 |
| 2011 | 6,170 |
| 2012 | 7,037 |
| 2013 | 5,700 |
| 2014 | 6,969 |
| 2015 | 10,116 |
| 2016 | 11,568 |
| 2017 | 11,253 |
| 2018 | 10,777 |
| 2019 | 11,027 |
| 2020 | 10,609 |
| 2021 | 9,335 |
| 2022 | 8,694 |
| 2023 | 7,640 |
| 2024 | 7,565 |
| 2025 | 7,560 |
| 2026 | 5,630 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Resolved · updated Nov 4, 2026
Klonopin, Tablet, 2 mg (NDC 61269-620-10).
Resolved · updated Nov 4, 2026
Klonopin, Tablet, .5 mg (NDC 61269-605-10).
Resolved · updated Nov 4, 2026
Klonopin, Tablet, 1 mg (NDC 61269-610-10).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Klonopin (Clonazepam)
2024 spending
$3.4M
Beneficiaries
2,323
14,868 claims
Per beneficiary
$1,466
$2.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,568,132 |
| 2021 | $4,412,317 |
| 2022 | $3,663,256 |
| 2023 | $3,683,535 |
| 2024 | $3,405,214 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review of treatment for patients with burning mouth syndrome.
Tan HL, Smith JG, Hoffmann J, et al. · Cephalalgia 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G, Meader N, Barbui C, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis.
Gerolymos C, Barazer R, Yon DK, et al. · JAMA Netw Open 2024 · Systematic Review, Network Meta-Analysis
- Clonazepam.
Browne TR · N Engl J Med 1978 · Clinical Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Dystonia.
Snaith A, Wade D · BMJ Clin Evid 2014 · Systematic Review
- The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials.
Skeie-Larsen M, Stave R, Grønli J, et al. · Int J Environ Res Public Health 2022 · Systematic Review, Meta-Analysis
Sponsor: Cheplapharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.